CA2579716A1 - Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at<sb>1</sb> - Google Patents

Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at<sb>1</sb> Download PDF

Info

Publication number
CA2579716A1
CA2579716A1 CA002579716A CA2579716A CA2579716A1 CA 2579716 A1 CA2579716 A1 CA 2579716A1 CA 002579716 A CA002579716 A CA 002579716A CA 2579716 A CA2579716 A CA 2579716A CA 2579716 A1 CA2579716 A1 CA 2579716A1
Authority
CA
Canada
Prior art keywords
alkyl
group
producing system
pharmaceutical composition
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002579716A
Other languages
English (en)
Inventor
Dieter Ziegler
Klaus Witte
Matthias Straub
Yvan Fischer
Dirk Thormaehlen
Dagmar Hoeltje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2579716A1 publication Critical patent/CA2579716A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une nouveau traitement combiné pour les maladies cardiovasculaires, en particulier l'hypertension artérielle essentielle, l'hypertension pulmonaire et/ou l'insuffisance cardiaque congestive, impliquant l'administration d'une combinaison synergique d'au moins un inhibiteur de l'endopeptidase neutre, d'au moins un inhibiteur du système de production de l'endothéline endogène et d'au moins un antagoniste du récepteur AT1.
CA002579716A 2004-06-23 2005-06-22 Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at<sb>1</sb> Abandoned CA2579716A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58172304P 2004-06-23 2004-06-23
US60/581,723 2004-06-23
EP04102906 2004-06-23
EP04102906.7 2004-06-23
PCT/EP2005/052915 WO2006000564A1 (fr) 2004-06-23 2005-06-22 Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1

Publications (1)

Publication Number Publication Date
CA2579716A1 true CA2579716A1 (fr) 2006-01-05

Family

ID=34979877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002579716A Abandoned CA2579716A1 (fr) 2004-06-23 2005-06-22 Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at<sb>1</sb>

Country Status (10)

Country Link
EP (1) EP1776095A1 (fr)
JP (1) JP2008503546A (fr)
CN (1) CN1972679B (fr)
AU (1) AU2005256634B2 (fr)
BR (1) BRPI0512379A (fr)
CA (1) CA2579716A1 (fr)
HK (1) HK1103638A1 (fr)
MX (1) MXPA06014448A (fr)
RU (1) RU2384346C2 (fr)
WO (1) WO2006000564A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054975A1 (fr) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
WO2007106708A2 (fr) * 2006-03-10 2007-09-20 Novartis Ag Combinaison de composes organiques
EP1891952B1 (fr) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Composition pharmaceutique d'olmésartan médoxomil
NZ594606A (en) 2009-01-30 2013-06-28 Takeda Pharmaceutical Fused ring compound and use thereof
US20180311241A1 (en) * 2015-10-29 2018-11-01 Cadila Healthcare Limited Pharmaceutical synergistic combination
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2018226991A1 (fr) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Dispositifs de déplacement de fluide intravasculaire, systèmes et procédés d'utilisation
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
EP4085965A1 (fr) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Pompes à sang intravasculaires et procédés d'utilisation et de fabrication
JP2022540616A (ja) 2019-07-12 2022-09-16 シファメド・ホールディングス・エルエルシー 血管内血液ポンプならびに製造および使用の方法
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
WO2021062270A1 (fr) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Pompes à sang de cathéter et boîtiers de pompe pliables
EP4034192A4 (fr) 2019-09-25 2023-11-29 Shifamed Holdings, LLC Dispositifs et systèmes de pompes à sang intravasculaires et leurs procédés d'utilisation et de commande

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1998018787A1 (fr) * 1996-10-29 1998-05-07 Merck & Co., Inc. Procede de cristallisation du losartan
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
WO2001015674A2 (fr) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Utilisation d'inhibiteurs du systeme renine-angiotensine dans la prevention de manifestations cardio-vasculaires
BR0209855A (pt) * 2001-05-18 2004-06-15 Solvay Pharm Gmbh Uso de compostos com atividade inibidora de nep/mp combinada na preparação de medicamentos
WO2003000712A1 (fr) * 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
DE60315795T2 (de) * 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
EP1578360A4 (fr) * 2002-08-28 2009-10-21 Curis Inc Administration conjointe de morphogenes et d'inhibiteurs de conversion de l'enzyme de l'angiotensine pour le traitement de l'insuffisance renale chronique
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid

Also Published As

Publication number Publication date
RU2007102227A (ru) 2008-07-27
RU2384346C2 (ru) 2010-03-20
WO2006000564A1 (fr) 2006-01-05
AU2005256634A1 (en) 2006-01-05
HK1103638A1 (en) 2007-12-28
JP2008503546A (ja) 2008-02-07
BRPI0512379A (pt) 2008-03-11
MXPA06014448A (es) 2007-03-01
CN1972679B (zh) 2010-07-28
CN1972679A (zh) 2007-05-30
EP1776095A1 (fr) 2007-04-25
AU2005256634B2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
AU2005256634B2 (en) Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists
JP4870888B2 (ja) 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
US20110229571A1 (en) Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker
US20100203132A1 (en) Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and AT1 Receptor Antagonists
WO2007053406A1 (fr) Combinaison de composes organiques hypotenseurs et hypocholesterolemiant
WO2007051007A2 (fr) Combinaison de composes organiques
US20070185065A1 (en) Combination therapy for coronary artery disease
EP1611886A2 (fr) Inhibiteurs du système renin-angiotensin destinés à la prévention des troubles cardio-vasculaires

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130225

FZDE Discontinued

Effective date: 20130225